Orexo PP&E per Employee
The PP&E per Employee of Orexo (ORX.ST) as of Jul 29, 2026 is 427,272.73 SEK. In the previous year, PP&E per Employee was 614,393.94 SEK — a change of -30.46% (lower).
Get this data via API
Financial Data API
PP&E per Employee
427,272.73SEK
YoY
-30.46%
Last updated:
PP&E per Employee of Orexo is 2026 427,272.73 SEK. PP&E per Employee of Orexo was 2025 614,393.94 SEK. It decreases by -30.46% lower compared to the previous year.
Access this data via the Eulerpool API
Orexo Stock analysis
What does Orexo do? Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders.
Business model:
Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology.
Divisions:
Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics.
Pharmaceuticals:
In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include:
- Zubsolv: a medication for the treatment of opioid addiction
- Abstral: a fast-acting pain medication for cancer patients
- Edluar: a sleep medication for the treatment of sleep disorders
Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms.
Digital therapeutics:
Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo.
History:
Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv.
In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide.
Products:
Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly.
Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction.
Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually.
Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success.
Conclusion:
Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation. Orexo is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Orexo stock
PP&E per Employee of Orexo is 427,272.73 SEK in 2026.
Access this data via the Eulerpool API
Workforce — Orexo
All Key Metrics — Orexo
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth